LIVIVO - Search results -

Search results

Result 1 - 10 of total 96

Search options

Article: [Chronic inflammatory bowel disease in elderly people].

Althaus, Dominic / Hruz, Petr

Therapeutische Umschau. Revue therapeutique

2023 Volume 80, Issue 9, Page(s) 405–410

Abstract: Introduction: Inflammatory bowel disease is mainly diagnosed in younger patients. However, the number of elderly patients (age > 60 years) affected by Crohn's disease or ulcerative colitis is increasing. In the elderly, symptoms often differ from the ... ...

Abstract	Introduction: Inflammatory bowel disease is mainly diagnosed in younger patients. However, the number of elderly patients (age > 60 years) affected by Crohn's disease or ulcerative colitis is increasing. In the elderly, symptoms often differ from the younger population. Older patients generally present a milder clinical course and are less often affected by extraintestinal disease activity. Treatment options are similar to the ones in younger patients. Due to the higher risk of drug interactions and side effects, comorbidities and comedication of the older patients play a pivotal role in the selection of the specific treatment agent. In therapy refractory disease, surgical treatment is also a valuable option for patients > 60 years. Furthermore, vaccination, prevention of infections and regular cancer screening is mandatory in this vulnerable population.
MeSH term(s)	Humans ; Aged ; Middle Aged ; Inflammatory Bowel Diseases/therapy ; Inflammatory Bowel Diseases/drug therapy ; Crohn Disease/diagnosis ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/drug therapy ; Intestines ; Chronic Disease
Language	German
Publishing date	2023-12-14
Publishing country	Switzerland
Document type	English Abstract ; Journal Article
ZDB-ID	82044-1
ISSN	1664-2864 ; 0040-5930
ISSN (online)	1664-2864
ISSN	0040-5930
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.180: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Defer No Time, Delays Have Dangerous Ends (William Shakespeare).

Biedermann, Luc / Straumann, Alex / Hruz, Petr

Gastroenterology

2021 Volume 161, Issue 1, Page(s) 42–44

MeSH term(s)	Administration, Topical ; Aftercare ; Anastomosis, Surgical ; Delayed Diagnosis ; Dilatation ; Eosinophilic Esophagitis/complications ; Esophageal Perforation/diagnosis ; Esophageal Perforation/etiology ; Esophageal Perforation/surgery ; Esophageal Stenosis/diagnosis ; Esophageal Stenosis/etiology ; Esophageal Stenosis/surgery ; Esophagectomy ; Esophagoscopy ; Esophagus/surgery ; Glucocorticoids/administration & dosage ; Humans ; Male ; Mediastinitis/diagnosis ; Mediastinitis/etiology ; Pleural Effusion/diagnosis ; Pleural Effusion/etiology ; Recurrence ; Stomach/surgery ; Time Factors ; Young Adult
Chemical Substances	Glucocorticoids
Language	English
Publishing date	2021-04-01
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	80112-4
ISSN	1528-0012 ; 0016-5085
ISSN (online)	1528-0012
ISSN	0016-5085
DOI	10.1053/j.gastro.2021.03.055
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui V Zs.44: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 572: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases.

Kaymak, Tanay / Hruz, Petr / Niess, Jan Hendrik

The FEBS journal

2021 Volume 289, Issue 16, Page(s) 4758–4772

Abstract: The gastrointestinal tract is the largest compartment of the body's immune system exposed to microorganisms, structural components and metabolites, antigens derived from the diet, and pathogens. Most studies have focused on immune responses in the ... ...

Abstract	The gastrointestinal tract is the largest compartment of the body's immune system exposed to microorganisms, structural components and metabolites, antigens derived from the diet, and pathogens. Most studies have focused on immune responses in the stomach, the small intestine, and the colon, but the esophagus has remained an understudied anatomic immune segment. Here, we discuss the esophagus' anatomical and physiological distinctions that may account for inflammatory esophageal diseases.
MeSH term(s)	Esophagus ; Immune System ; Intestine, Small ; Microbiota ; Stomach
Language	English
Publishing date	2021-07-13
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2173655-8
ISSN	1742-4658 ; 1742-464X
ISSN (online)	1742-4658
ISSN	1742-464X
DOI	10.1111/febs.16103
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 260: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Epidemiology of eosinophilic esophagitis.

Hruz, Petr

Digestive diseases (Basel, Switzerland)

2014 Volume 32, Issue 1-2, Page(s) 40–47

Abstract: Eosinophilic esophagitis (EoE) is an allergy-associated disease defined clinically by esophagus-related symptoms in combination with a dense esophageal eosinophilia, both of which are unresponsive to prolonged acid suppression with proton pump inhibitors. ...

Abstract	Eosinophilic esophagitis (EoE) is an allergy-associated disease defined clinically by esophagus-related symptoms in combination with a dense esophageal eosinophilia, both of which are unresponsive to prolonged acid suppression with proton pump inhibitors. Over the last two decades EoE has increasingly been recognized in various geographical areas (mostly industrialized countries) with high socioeconomic development. The prevalence rate is increasing and reaches up to 50 patients per 100,000 inhabitants in some indicator regions. Whether this increased prevalence is due to a real increase in incidence, a result of increased awareness by health care providers or because of the nonfatal nature of EoE adding more and more cases to the patient pool is still a matter of controversy. Several studies have consistently demonstrated a male predominance in EoE, with a male-to-female risk ratio of 3:1. The average age at diagnosis ranges between 30 and 50 years and suggests that EoE is a disease of the middle-aged man. It can affect patients of every race, but the disease is more common among Caucasians. In both children and adults, EoE has been clearly associated with allergies to food and aeroallergens, and most EoE patients present with a personal allergic background (e.g. asthma, rhinoconjunctivitis or oral allergy syndrome). In conclusion, knowledge of epidemiologic parameters of EoE is crucial for identifying risk factors as well as pathogenic mechanisms, planning preventive measures and determining optimal treatment strategies.
MeSH term(s)	Eosinophilic Esophagitis/complications ; Eosinophilic Esophagitis/epidemiology ; Eosinophilic Esophagitis/pathology ; Esophagoscopy ; Geography ; Humans ; Hypersensitivity/complications ; Incidence ; Prevalence
Language	English
Publishing date	2014
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	632798-9
ISSN	1421-9875 ; 0257-2753
ISSN (online)	1421-9875
ISSN	0257-2753
DOI	10.1159/000357008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1853: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Gastroenterologische Entzündungen. EoE: Ein neues Krankheitsbild besser verstehen / CME-Fortbildungsfragen

Hruz, Petr

Hausarzt-Praxis

2016 Volume 11, Issue 12, Page(s) 7/21

Language	German
Document type	Article
ZDB-ID	2229849-6
ISSN	1661-6197
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Zs.A 6266: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients.

Sutter, Manuel / Hruz, Petr / Niess, Jan Hendrik

Inflammatory intestinal diseases

2021 Volume 6, Issue 3, Page(s) 165–174

Abstract: Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD). Whether high serum CK levels are a specific ... ...

Abstract	Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD). Whether high serum CK levels are a specific effect of treatment with TNF inhibitors has not been studied in detail. CK levels were therefore compared between infliximab- and vedolizumab-treated IBD patients. Methods: In this retrospective, monocentric study, 131 IBD cases (82 with Crohn's disease (CD), 49 with ulcerative colitis) of the Basel University Hospital IBD cohort treated either with infliximab or vedolizumab were included. Serum samples for measuring CK, lactate dehydrogenase (LDH), C-reactive protein (CRP), and fecal calprotectin (FCal) levels were collected longitudinally and analyzed using mixed additive models. Results: No significant differences in CK levels between infliximab and vedolizumab-treated patients were observed over time. Infliximab-treated males, however, showed significantly higher CK levels than females and former smokers treated with infliximab showed significantly lower CK levels than nonsmokers. No such differences were observed in vedolizumab-treated patients. LDH and CRP were not significantly different between infliximab- and vedolizumab-treated patients, while adjusted groups showed substantially higher LDH levels with increasing age and significantly lower LDH levels in patients with longer disease duration. Infliximab patients with CD showed significantly lower CRP. However, significantly higher FCal concentrations were noted in infliximab patients independent of diagnosis, gender, disease duration, smoking behavior, and age. Conclusion: In our cohort, high serum CK levels are not an infliximab- or vedolizumab-specific effect.
Language	English
Publishing date	2021-08-26
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2817967-5
ISSN	2296-9365 ; 2296-9403
ISSN (online)	2296-9365
ISSN	2296-9403
DOI	10.1159/000518264
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Faecal calprotectin increases the diagnostic yield in patients with suspected small bowel disease - a multicenter retrospective cohort study.

Abo El Ela, Aisha / Meuli, Nina / Hruz, Petr / Burri, Emanuel

Swiss medical weekly

2022 Volume 153, Page(s) 40050

Abstract: Aim of the study: Diagnosing small bowel pathology is challenging, and the diagnostic yield of small bowel capsule endoscopy is highly variable. Faecal calprotectin is a non-invasive intestinal inflammation marker that could be used as a selection tool ... ...

Abstract	Aim of the study: Diagnosing small bowel pathology is challenging, and the diagnostic yield of small bowel capsule endoscopy is highly variable. Faecal calprotectin is a non-invasive intestinal inflammation marker that could be used as a selection tool to identify patients who might benefit from small bowel capsule endoscopy and increase its diagnostic yield. This study aimed to investigate the value of faecal calprotectin in detecting small bowel lesions in an unselected patient population. Methods: We performed a retrospective analysis of consecutive patients who underwent small bowel capsule endoscopy at the University Hospital Basel and the University Medical Clinic Cantonal Hospital Baselland, Switzerland, between 2010 and 2018. Patients without faecal calprotectin testing were excluded from the analysis. The primary endpoint was the presence of a clinically significant small bowel finding. Results: Patients with positive faecal calprotectin results were more likely to have small bowel findings (66.7% vs 39.4%; P = 0.007). The optimal faecal calprotectin cut-off to identify clinically significant small bowel lesions was 63 μg/g with 78.3% (95% confidence interval: 66.7-87.9) sensitivity, 47.9% (33.3-62.8) specificity, 1.50 (1.1-2.0) positive and 0.45 (0.3-0.8) negative likelihood ratios, 68.4% (61.6-74.4) positive and 60.5% (47.3-72.4) negative predictive values, and 65.0% overall accuracy. Faecal calprotectin performed best in patients with suspected inflammatory bowel disease, with 66.7% (48.2-82.0) sensitivity, 70.6% (44.0-89.7) specificity, 2.27 (1.0-4.9) positive and 0.47 (0.3-0.8) negative likelihood ratios, 81.5% (67.0-90.5) positive and 54.5% (39.7-68.6) negative predictive values, and 71.4% overall accuracy. Conclusion: Faecal calprotectin testing increases the diagnostic yield of small bowel capsule endoscopy and may help identify patients at risk of small bowel disease.
MeSH term(s)	Humans ; Retrospective Studies ; Leukocyte L1 Antigen Complex ; Biomarkers ; Inflammatory Bowel Diseases ; Intestine, Small/pathology
Chemical Substances	Leukocyte L1 Antigen Complex ; Biomarkers
Language	English
Publishing date	2022-03-22
Publishing country	Switzerland
Document type	Multicenter Study ; Journal Article
ZDB-ID	2036179-8
ISSN	1424-3997 ; 1424-7860
ISSN (online)	1424-3997
ISSN	1424-7860
DOI	10.57187/smw.2023.40050
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.152: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases

Kaymak, Tanay / Hruz, Petr / Niess, Jan Hendrik

FEBS journal. 2022 Aug., v. 289, no. 16

2022

Abstract	The gastrointestinal tract is the largest compartment of the body's immune system exposed to microorganisms, structural components and metabolites, antigens derived from the diet, and pathogens. Most studies have focused on immune responses in the stomach, the small intestine, and the colon, but the esophagus has remained an understudied anatomic immune segment. Here, we discuss the esophagus' anatomical and physiological distinctions that may account for inflammatory esophageal diseases.
Keywords	colon ; diet ; digestive tract ; esophagus ; immune system ; metabolites ; microbiome ; small intestine ; stomach
Language	English
Dates of publication	2022-08
Size	p. 4758-4772.
Publishing place	John Wiley & Sons, Ltd
Document type	Article
Note	REVIEW
ZDB-ID	2173655-8
ISSN	1742-4658 ; 1742-464X
ISSN (online)	1742-4658
ISSN	1742-464X
DOI	10.1111/febs.16103
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 2006/704: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice.

Rossier, Laura / Matter, Christoph / Burri, Emanuel / Galperine, Tatiana / Hrúz, Petr / Juillerat, Pascal / Schoepfer, Alain / Vavricka, Stephan R / Zahnd, Nadine / Décosterd, Natalie / Seibold, Frank

Swiss medical weekly

2023 Volume 153, Page(s) 40100

Abstract: Introduction: Faecal microbiota transplantation (FMT) is an established therapy for recurrent C. difficile infection, and recent studies have reported encouraging results of FMT in patients with ulcerative colitis. Few international consensus guidelines ...

Abstract	Introduction: Faecal microbiota transplantation (FMT) is an established therapy for recurrent C. difficile infection, and recent studies have reported encouraging results of FMT in patients with ulcerative colitis. Few international consensus guidelines exist for this therapy, and thus FMT policies and practices differ among European countries. As of 2019, stool transplants are considered a non-standardised medicinal product in Switzerland, and a standardised production process requires authorisation by the Swiss Agency for Therapeutic Products. This authorisation leads to prolonged administrative procedures and increasing costs, which reduces treatment accessibility. In particular, patients with ulcerative colitis in Switzerland can only benefit from FMT off-label, even though it is a valid therapeutic option. Therefore, this study summarised the available data on FMT and established a framework for the standardised use of FMT. Methods: A panel of Swiss gastroenterologists with a special interest in inflammatory bowel disease was established to identify the current key issues of FMT. After a comprehensive review of the literature, statements were formulated about FMT indications, donor screening, stool transplant preparation and administration, and safety aspects. The panel then voted on the statements following the Delphi process; the statements were reformulated and revoted until a consensus was reached. The manuscript was then reviewed by an infectiologist (the head of Lausanne's FMT centre). Results: The established statements are summarised in the supplementary tables in the appendix to this paper. The working group hopes these will help standardise FMT practice in Switzerland and contribute to making faecal microbiota transplantation a safe and accessible treatment for patients with recurrent C. difficile infections and selected patients with ulcerative colitis, as well as other indications in the future.
MeSH term(s)	Humans ; Clostridioides difficile ; Clostridium Infections/microbiology ; Clostridium Infections/therapy ; Colitis, Ulcerative/etiology ; Colitis, Ulcerative/therapy ; Fecal Microbiota Transplantation/adverse effects ; Fecal Microbiota Transplantation/methods ; Inflammatory Bowel Diseases/therapy ; Switzerland ; Treatment Outcome
Language	English
Publishing date	2023-08-25
Publishing country	Switzerland
Document type	Journal Article ; Review ; Systematic Review
ZDB-ID	2036179-8
ISSN	1424-3997 ; 1424-7860
ISSN (online)	1424-3997
ISSN	1424-7860
DOI	10.57187/smw.2023.40100
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.152: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Amoebic Liver Abscess in Crohn Disease Treated With Ustekinumab.

Rybinski, Florian / Weisser, Maja / Niess, Jan Hendrik / Hruz, Petr

Inflammatory bowel diseases

2020 Volume 26, Issue 7, Page(s) e68

MeSH term(s)	Crohn Disease/drug therapy ; Crohn Disease/parasitology ; Humans ; Immunologic Factors/adverse effects ; Liver Abscess, Amebic/chemically induced ; Liver Abscess, Amebic/parasitology ; Male ; Medical Illustration ; Middle Aged ; Ustekinumab/adverse effects
Chemical Substances	Immunologic Factors ; Ustekinumab (FU77B4U5Z0)
Language	English
Publishing date	2020-05-12
Publishing country	England
Document type	Case Reports ; Letter
ZDB-ID	1340971-2
ISSN	1536-4844 ; 1078-0998
ISSN (online)	1536-4844
ISSN	1078-0998
DOI	10.1093/ibd/izaa101
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4530: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito